Table 2.
AE, n (%) | All patients (N = 60) |
---|---|
Any-grade AEs | 60 (100.0) |
Grade ≥3 AEs | 30 (50.0) |
Grade 5 AEs | 4 (6.7) |
Serious AEs | 19 (31.7) |
AEs leading to taselisib dose modifications | |
AE leading to taselisib dose reduction | 14 (23.3) |
AE leading to taselisib dose interruption | 27 (45.0) |
AE leading to taselisib discontinuation | 12 (20.0) |